World Journal of Pediatrics

, Volume 12, Issue 3, pp 283–290 | Cite as

Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis

  • Ivana Đurić-Filipović
  • Marco Caminati
  • Gordana Kostić
  • Đorđe Filipović
  • Zorica Živković
Review article



The incidence of asthma and allergic rhinitis (AR) is significantly increased, especially in younger children. Current treatment for children with asthma and allergic rhinitis include allergen avoidance, standard pharmacotherapy, and immunotherapy. Since standard pharmacotherapy is prescribed for symptoms, immunotherapy at present plays an important role in the treatment of allergic diseases. This article presents insights into the up-to-date understanding of immunotherapy in the treatment of children with allergic rhinitis and asthma.

Data sources

PubMed articles published from 1990 to 2014 were reviewed using the MeSH terms "asthma", "allergic rhinitis", "children", and "immune therapy". Additional articles were identified by hand searching of the references in the initial search.


Numerous studies have shown that sublingual application of allergen specific immunotherapy (SLIT) is an adequate, safe and efficient substitution to subcutaneous route of allergens administration (SCIT) in the treatment of IgE-mediated respiratory tract allergies in children. According to the literature, better clinical efficacy is connected with the duration of treatment and mono sensitized patients.


At least 3 years of treatment and stable asthma before the immunotherapy are positive predictors of good clinical efficacy and tolerability of SLIT. SLIT reduces the symptoms of allergic diseases and the use of medicaments, and improves the quality of life of children with the diseases.

Key words

allergic asthma allergic rhinitis allergic sensitization immunotherapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper J Allergy Clin Immunol 1998;102:558–622.CrossRefPubMedGoogle Scholar
  2. 2.
    Black JH. The oral administration of pollen: clinical report. J Lab Clin Med 1928;13:709–713.Google Scholar
  3. 3.
    Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006;61:151–165.CrossRefPubMedGoogle Scholar
  4. 4.
    Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338–1345.CrossRefPubMedGoogle Scholar
  5. 5.
    Dahl R, Kapp A, Colombo G, de Monchy JGR, Rak S, Emminger W, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008;121:512–518.CrossRefPubMedGoogle Scholar
  6. 6.
    Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:3252–3259.CrossRefPubMedGoogle Scholar
  7. 7.
    UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319–325.CrossRefGoogle Scholar
  8. 8.
    Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006;17:408–415.CrossRefPubMedGoogle Scholar
  9. 9.
    Rolinck-Werninghaus C, Kopp M, Liebke C, Lange J, Wahn U, Niggemann B. Lack of detectable alterations in immune responses during sublingual immunotherapy in children seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005;136:134–141.CrossRefPubMedGoogle Scholar
  10. 10.
    Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebocontrolled study. Allergy 2000;55:842–849.CrossRefPubMedGoogle Scholar
  11. 11.
    Bahceciler NN, Arikan C, Taylor A, Akdis M, Blaser K, Barlan IB, et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005;136:287–294.CrossRefPubMedGoogle Scholar
  12. 12.
    Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, et al. Immune responses in healthy and allergic Individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199:1567–1575.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Mantel PY, Kuipers H, Boyman O, Rhyner C, Ouaked N, Ruckert B, et al. GATA3-driven Th2 responses inhibit TGFbeta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 2007;5:e329.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012;30:221–224CrossRefPubMedGoogle Scholar
  15. 15.
    Laaksonen K, Junikka M, Lahesmaa R, Terho EO, Savolainen J. In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy. J Allergy Clin Immunol 2003;112:1171–1177.CrossRefPubMedGoogle Scholar
  16. 16.
    Gabrielsson S, Soderlund A, Paulie S, van der Pouw Kraan TC, Troye-Blomberg M, Rak S. Specific immunotherapy prevents increased levels of allergen-specific IL-4 and IL-13-producing cells during pollen season. Allergy 2001;56:293–300.CrossRefPubMedGoogle Scholar
  17. 17.
    Faith A, Richards DF, Verhoef A, Lamb JR, Lee TH, Hawrylowicz CM. Impaired secretion of interleukin-4 and interleukin-13 by allergen-specific T cells correlates with defective nuclear expression of NF-AT2 and jun B: relevance to immunotherapy. Clin Exp Allergy 2003;33:1209–1215.CrossRefPubMedGoogle Scholar
  18. 18.
    Oldfield WL, Larché M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002;360:47–53.CrossRefPubMedGoogle Scholar
  19. 19.
    Ippoliti F, De Santis W, Volterrani A, Lenti L, Canitano N, Lucarelli S, et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003;14:216–221.CrossRefPubMedGoogle Scholar
  20. 20.
    Fenoglio D, Puppo F, Cirillo I, Vizzaccaro A, Ferrera A, Tosca MAet al. Sublingual specific immunotherapy reduces PBMC proliferations. Eur Ann Allergy Clin Immunol 2005;37:147–151.PubMedGoogle Scholar
  21. 21.
    Suárez-Fueyo A, Ramos T, Galán A, Jimeno L, Wurtzen PA, Marin A, et al. Grass tablet sublingual immunotherapy down regulates the TH2 cytokine response followed by regulatory T-cell generation. J Allergy Clin Immunol 2014;133:130–138.CrossRefPubMedGoogle Scholar
  22. 22.
    Hawrylowicz CM, O’Garra A. Potential role of interleukin-10 secreting regulatory T cells in allergy and asthma. Nature Rev Immunol 2005;5:271–283.CrossRefGoogle Scholar
  23. 23.
    Taylor A, Verhagen J, Akdis CA, Akdis M. T regulatory cells in allergy and health: a question of allergen specificity and balance. Int Arch Allergy Immunol 2004;135:73–82.CrossRefPubMedGoogle Scholar
  24. 24.
    Yazdanbakhsh M, Kremsner PG, Van Ree R. Allergy, parasites and the hygiene hypothesis. Science 2002;296:490–494.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhang L, Zhao Y. The regulation of Foxp3 expression in regulatory CD4(1) CD25(1)T cells: multiple pathways on the road. J Cell Physiol 2007;211:590–597.CrossRefPubMedGoogle Scholar
  26. 26.
    Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006;441:231–234.CrossRefPubMedGoogle Scholar
  27. 27.
    Gambineri E, Torgerson T, Ochs H. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of Foxp3, a critical regulator of T cell homeostasis. Curr Opin Rhumatol 2003;15:430–435.CrossRefGoogle Scholar
  28. 28.
    Gentile D, Schreiber R, Howe-Adams J, Trecki J, Patel A, Angelini B, et al. Diminished dendritic cell interleukin 10 production in atopic children. Ann Allergy Asthma Immunol 2004;92:538–544.CrossRefPubMedGoogle Scholar
  29. 29.
    Ling EM. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004;363:608–615.CrossRefPubMedGoogle Scholar
  30. 30.
    Akdis C, Joss A, Akdis M, Blaser K. Mechanisms of IL10 induced T cell inactivation in allergic inflammation and normal response to allergens. Int Arch Allergy Immunol 2001;124:180–182.CrossRefPubMedGoogle Scholar
  31. 31.
    Akdis M, Akdis C. Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 2014;133:621–631.CrossRefPubMedGoogle Scholar
  32. 32.
    Tari G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A doubleblind study. Allergol Immunopathol (Madr) 1990;18:277–284.Google Scholar
  33. 33.
    Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D. pt. ) in children. Pediatr Allergy Immunol 1997;8:21–27.CrossRefPubMedGoogle Scholar
  34. 34.
    Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, André C, et al. Double blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53:662–672.CrossRefPubMedGoogle Scholar
  35. 35.
    La Rosa M, Ranno C, André C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104:425–432.CrossRefPubMedGoogle Scholar
  36. 36.
    Caffarelli C, Sensi LG, Marcucci F, Cavagni C. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000;55:1142–1147.CrossRefPubMedGoogle Scholar
  37. 37.
    Yuksel H, Tanac R, Gousseinov A, Demir E. Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy. J Investig Allergol Clin Immunol 1999;9:305–313.PubMedGoogle Scholar
  38. 38.
    Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001;32:49–55.CrossRefPubMedGoogle Scholar
  39. 39.
    Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003;33:1641–1647.CrossRefPubMedGoogle Scholar
  40. 40.
    Wuthrich B, Bucher Ch, Jorg W, Bircher A, Eng P, Schneider Y, et al. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. J Investig Allergol Clin Immunol 2003;13:145–148.PubMedGoogle Scholar
  41. 41.
    Bufe A, Ziegler-Kirbach E, Stoeckmann E, Heidemann P, Gehlhar K, Klimek L, et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004;59:498–504.CrossRefPubMedGoogle Scholar
  42. 42.
    Niu CK, Chen WY, Huang JL, Lue KH, Wang JY. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multicenter, double-blind, randomized, and placebocontrolled study in Taiwan. Respir Med 2006;100:1374–1383.CrossRefPubMedGoogle Scholar
  43. 43.
    Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006;61:1177–1183.CrossRefPubMedGoogle Scholar
  44. 44.
    Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust miteinduced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007;18:47–57.CrossRefPubMedGoogle Scholar
  45. 45.
    Roder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007;119:892–898.CrossRefPubMedGoogle Scholar
  46. 46.
    Wahn U, Tabar A, Kuna P, Halken S, Montagut A, De Beaumont O. Efficacy and safety of 5 grass pollen subllingualimmunotherapy in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160–166.CrossRefPubMedGoogle Scholar
  47. 47.
    Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al. Safety anefficacy in children of an SQstandardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167–173.CrossRefPubMedGoogle Scholar
  48. 48.
    Stelmach I, Kaczmarek-Wozniak J, Majak P, Olszowiec-Chlebna M, Jerzynska J. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy 2009;39:401–408.CrossRefPubMedGoogle Scholar
  49. 49.
    Marcucci F, Sensi L, Di Cara G, Incorvaia C, Frati F. Dose dependence of immunological response to sublingual immunotherapy Allergy 2005;60:952–956.CrossRefPubMedGoogle Scholar
  50. 50.
    Larenas-Linnemann D, Blaiss M, Van Bever HP, Compalati E, Baena-Cagnani CE Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. Ann Allergy Asthma Immunol 2013;110:402–415.CrossRefPubMedGoogle Scholar
  51. 51.
    Hedlin G, van HM. The role of immuntherapy in the managment of childhood asthma. Ther Adv Respir Dis 2012;127:30–38.Google Scholar
  52. 52.
    Tabar AI, Arroabarren E, Echechipía S, García BE, Martin S, Alvarez-Puebla MJ. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011;127:57–63.CrossRefPubMedGoogle Scholar
  53. 53.
    Ozdemir C, Yazi D, Gocmen I, Yesil O, Aydogan M, Semic-Jusufagic A, et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol 2007;18:508–515.CrossRefPubMedGoogle Scholar
  54. 54.
    Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen specific immunotherapy in childrem with asthma: a randomized controled trial. J Allergy Clin Immunol 2010;126:942–956.CrossRefPubMedGoogle Scholar
  55. 55.
    Lin SY, Erekosima N, Kim JM, Ramanathan M, Suarez-Cuervo C, Chelladurai Y, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjuntivits and asthma. JAMA 2013;309:1278–1288.CrossRefPubMedGoogle Scholar
  56. 56.
    Bachert C, Canonica GW, Bufe A. SIT: efficacy depends on product, not on route of application. Pediatr Allergy Immunol 2012;23:401.CrossRefPubMedGoogle Scholar
  57. 57.
    Yoselin A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 2012;157:288–298.Google Scholar
  58. 58.
    Aydogan M, Eifan AO, Keles S, Akkoc T, Nursoy MA, Bahceciler NN, et al. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. Respir Med 2013;107:1322–1329.CrossRefPubMedGoogle Scholar
  59. 59.
    Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011;127:64–71, 71. e1-4.CrossRefPubMedGoogle Scholar
  60. 60.
    Rodriguez-Perez N, Ambriz-Moreno AJ, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol 2008;101:304–310.CrossRefPubMedGoogle Scholar
  61. 61.
    Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006;61:1236–1237.CrossRefPubMedGoogle Scholar
  62. 62.
    Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008;63:374.CrossRefPubMedGoogle Scholar
  63. 63.
    de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immuno-therapy with grass pollen tablet. Allergy 2009;64:963–964.CrossRefPubMedGoogle Scholar
  64. 64.
    Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Postmarketing surveillance study on the safety of sublingual immunotherapy in children. Allergy 1999;54:1110–1113.CrossRefPubMedGoogle Scholar
  65. 65.
    Drachenberg KJ, Urban E, Proll S, Woroniecki SR. Sublingual specific immunotherapy for adults and children: a post marketing survey. Allergol Immunopathol 2004;32:76–81.CrossRefGoogle Scholar
  66. 66.
    Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy 2005;60:133.CrossRefPubMedGoogle Scholar
  67. 67.
    Rienzo VD, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG, et al. Post marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005;35:560–564.CrossRefPubMedGoogle Scholar
  68. 68.
    Fiocchi A, Pajno G, La Grutta S, Pezzuto F, Incorvaia C, Sensi L, et al. Safety of SLIT in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005;95:254–258.CrossRefPubMedGoogle Scholar
  69. 69.
    Agostinis F, Foglia C, Landi M, Cottini M, Lombardi C, Canonica GW, et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy 2008;63:1637–1639.CrossRefPubMedGoogle Scholar
  70. 70.
    De Castro G, Zicari AM, Indinnimeo L, Tancredi G, di Coste A, Occasi F, et al. Efficacy of sublilngual immunotherapy on allergic asthma in children’s real life. Eur Rev Med Pharmacol Sci 2013;17:2225–2231.PubMedGoogle Scholar
  71. 71.
    Caminati M, Dama A, Schiappoli M, Senna G. Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? Expert Rev Clin Immunol 2013;9:937–947.CrossRefPubMedGoogle Scholar
  72. 72.
    Calderón MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67:302–311.CrossRefPubMedGoogle Scholar
  73. 73.
    Passalacqua G, Canonica GW. Specific immunotherapy in asthma: efficacy and safety. Clin Exp Allergy 2011;41:1247–1255.CrossRefPubMedGoogle Scholar
  74. 74.
    Medical Dictionary for Regulatory Activities (MedDRA). Maintenance support services and organization. (Accessed October 1, 2014).Google Scholar
  75. 75.
    Senna G, Ridolo E, Calderon M, Lombardi C, Canonica GW, Passalacqua G. Evidence of adherence to immunotherapy. Curr Opin Allergy Clin Immunol 2009;9:544–548.CrossRefPubMedGoogle Scholar
  76. 76.
    Pajno GB, Caminiti L, Crisafulli G, Barberi S, Landi M, Aversa T, et al. Adherence to sublingual immunotherapy in preschool children. Pediatr Allergy Immunol 2012;23:688–689.CrossRefPubMedGoogle Scholar
  77. 77.
    Senna G, Caminati M, Canonica GW. Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Curr Opin Allergy Clin Immunol 2013;13:656–662.CrossRefPubMedGoogle Scholar
  78. 78.
    Passalacqua G, Baena-Cagnani CE, Bousquet J, Canonica GW, Casale TB, Cox L, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 2013;132:93–98.CrossRefPubMedGoogle Scholar
  79. 79.
    Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trias in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77–83.CrossRefPubMedGoogle Scholar
  80. 80.
    Ciprandi G, Cadario G, Valle C, Ridolo E, Verini M, Di Gioacchino M, et al. Sublingual immunotherapy in polysensitized patients: effect on quality of life. J Investig Allergol Clin Immunol 2010;20:274–279.PubMedGoogle Scholar
  81. 81.
    Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, et al. Sublingual swallow immunotherapy (SLIT) in patients with asthma due to house dust mites; a double blind placebo controlled study. Allergy 1999;54:249–260.CrossRefPubMedGoogle Scholar
  82. 82.
    Khinchi MS, Poulsen LK, Carat F, André C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004;59:45–53.CrossRefPubMedGoogle Scholar
  83. 83.
    Kahlert H, Grage-Griebenow E, Stüwe HT, Cromwell O, Fiebig H. T cell reactivity with allergoids: influence of the type of APC. J Immunol 2000;165:1807–1815.CrossRefPubMedGoogle Scholar
  84. 84.
    Ulrich JT1, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 1995;6:495–524.CrossRefPubMedGoogle Scholar

Copyright information

© Children's Hospital, Zhejiang University School of Medicine and Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Ivana Đurić-Filipović
    • 1
  • Marco Caminati
    • 2
  • Gordana Kostić
    • 3
  • Đorđe Filipović
    • 4
  • Zorica Živković
    • 5
  1. 1.Faculty of Medical Science KragujevacDepartment of ImmunologyKragujevacSerbia
  2. 2.Unita di Allergologia Centro Regionale di riferimento per la prevenzione, la diagnosi e la terapia delle malattie allergiche Ospedale Universitario Borgo TrentoVeronaItaly
  3. 3.Children’s HospitalClinical Centre KragujevacKragujevacSerbia
  4. 4.Institution for Emergency Medical CareBelgradeSerbia
  5. 5.Children’s Hospital for Lung Diseases and TuberculosisMedical Center “Dr Dragisa Misovic”BelgradeSerbia

Personalised recommendations